332 related articles for article (PubMed ID: 11711678)
1. Tumor therapy with targeted atomic nanogenerators.
McDevitt MR; Ma D; Lai LT; Simon J; Borchardt P; Frank RK; Wu K; Pellegrini V; Curcio MJ; Miederer M; Bander NH; Scheinberg DA
Science; 2001 Nov; 294(5546):1537-40. PubMed ID: 11711678
[TBL] [Abstract][Full Text] [Related]
2. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
Zalutsky MR; Bigner DD
Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
[TBL] [Abstract][Full Text] [Related]
4. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.
Miederer M; McDevitt MR; Borchardt P; Bergman I; Kramer K; Cheung NK; Scheinberg DA
Clin Cancer Res; 2004 Oct; 10(20):6985-92. PubMed ID: 15501978
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
Dahle J; Borrebaek J; Jonasdottir TJ; Hjelmerud AK; Melhus KB; Bruland ØS; Press OW; Larsen RH
Blood; 2007 Sep; 110(6):2049-56. PubMed ID: 17536011
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy with α-particle-emitting radionuclides.
Seidl C
Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
[TBL] [Abstract][Full Text] [Related]
7. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Minnix M; Li L; Yazaki PJ; Miller AD; Chea J; Poku E; Liu A; Wong JYC; Rockne RC; Colcher D; Shively JE
J Nucl Med; 2021 Jan; 62(1):55-61. PubMed ID: 32620701
[TBL] [Abstract][Full Text] [Related]
8. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
9. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M
Crit Rev Oncol Hematol; 2001; 39(1-2):139-46. PubMed ID: 11418311
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of human tumours.
Larson SM; Carrasquillo JA; Cheung NK; Press OW
Nat Rev Cancer; 2015 Jun; 15(6):347-60. PubMed ID: 25998714
[TBL] [Abstract][Full Text] [Related]
11. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
14. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
15. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
16. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
Zalutsky MR
J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
[No Abstract] [Full Text] [Related]
17. Targeted alpha therapy of prostate cancer.
Allen BJ; Li Y; Rizvi SM; Russell PJ
Methods Mol Med; 2003; 81():333-57. PubMed ID: 12725130
[No Abstract] [Full Text] [Related]
18. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
20. Targeted alpha-therapy for control of micrometastatic prostate cancer.
Li Y; Russell PJ; Allen BJ
Expert Rev Anticancer Ther; 2004 Jun; 4(3):459-68. PubMed ID: 15161444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
